Journals / The Anatolian Journal of Cardiology / 2022 / Cilt: 26 - Sayı: 2

Relationship between atherogenic index of plasma and stent thrombosis in patients with acute coronary syndrome

Pages
112–117
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: AIP is an easy calculable biomarker, and the performance of AIP to predict ST is better than TG/HDL-C.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Stent thrombosis (ST) is an uncommon but serious complication in patients undergoing percutaneous coronary intervention (PCI).
📊
Key Findings & Data:Methods: Among the 10,258 patients who underwent coronary angiography between January 2018 and December 2020, 239 patients who underwent PCI with the diagnosis of acute coronary syndrome (ACS) due to ST were included as the study group (ST group) and 459 patients who underwent percutaneous intervention for ACS and did not have any in-stent lesion as the control group (non-ST group).
💡
Conclusion & Impact:Conclusion: AIP is an easy calculable biomarker, and the performance of AIP to predict ST is better than TG/HDL-C.
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: Stent thrombosis (ST) is an uncommon but serious complication in patients undergoing percutaneous coronary intervention (PCI). This study aimed to investigate the effect of atherogenic index of plasma (AIP) on ST. Methods: Among the 10,258 patients who underwent coronary angiography between January 2018 and December 2020, 239 patients who underwent PCI with the diagnosis of acute coronary syndrome (ACS) due to ST were included as the study group (ST group) and 459 patients who underwent percutaneous intervention for ACS and did not have any in-stent lesion as the control group (non-ST group). ST classification was done according to the Academic Research Consortium definition. Results: The mean age of the patients was 63.3±10.6 years (483 male, 69.2%). The groups were similar in terms of characteristic properties, comorbidities, and the drugs being used (p>0.05 for all). Drug eluting stents were used in 86.5% of the patients. In the ST group, the median time from stent implantation to thrombosis was 285 days. Mean AIP and the ratio of triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) were statistically significantly higher in the ST group than in the controls (p<0.001 and p=0.018, respectively), and a positive correlation was observed between time from stent implantation to thrombosis and AIP and TG/HDL-C (rS=0.229, p=0.010 and rS=0.222, p=0.010, respectively). Multivariate logistic regression analysis revealed that stent length, prior ST elevation myocardial infarction, TG/HDL-C, and AIP were independent predictors of ST. Conclusion: AIP is an easy calculable biomarker, and the performance of AIP to predict ST is better than TG/HDL-C.

🔖

Cite This Article

ABACIOĞLU, Ö. Ö., YILDIRIM, A., KOYUNSEVER, N. Y., KARADENİZ, M., KILIÇ, S. (2022). Relationship between atherogenic index of plasma and stent thrombosis in patients with acute coronary syndrome. The Anatolian Journal of Cardiology, Cilt: 26 - Sayı: 2, 112–117. https://ajindex.com/articles/407443

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Reejhsinghani R, Lotfi AS. Prevention of stent thrombosis: challenges and solutions. Vasc Health Risk Manag 2015
  2. [Crossref] 2. Gori T, Polimeni A, Indolfi C, Räber L, Adriaenssens T, Münzel T. Predictors of stent thrombosis and their implications for clinical practice. Nat Rev Cardiol 2019
  3. [Crossref] 3. Claessen BE, Henriques JP, Jaffer FA, Mehran R, Piek JJ, Dangas GD. Stent thrombosis: a clinical perspective. JACC Cardiovasc Interv 2014
  4. [Crossref] 4. Takayama T, Hiro T, Hirayama A. Stent thrombosis and drug-eluting stents. J Cardiol 2011
  5. [Crossref] 5. de Souza DG, Baum VC, Ballert NM. Late thrombosis of a drug-eluting stent presenting in the perioperative period. Anesthesiology 2007
  6. [Crossref] 6. Wang X, Chen X, Sun W, Tian T, Zhou S, Zhang Z, et al. Very Late Stent Thrombosis in Drug-Eluting Stents New Observations and Clinical Implications. Cardiol Rev 2019
  7. [Crossref] 7. Cuesta J, Rivero F, Bastante T, García-Guimaraes M, Antuña P, Alvarado T, et al. Optical Coherence Tomography Findings in Patients With Stent Thrombosis. Rev Esp Cardiol (Engl Ed) 2017
  8. [Crossref] 8. Otsuka F, Nakano M, Ladich E, Kolodgie FD, Virmani R. Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement. Thrombosis 2012
  9. 608593. [Crossref] 9. Collet C, Sotomi Y, Cavalcante R, Suwannasom P, Tenekecioglu E, Onuma Y, et al. Coronary stent thrombosis: what have we learned? J Thorac Dis 2016
  10. [Crossref] 10. Lee SY, Hong MK. Mechanisms of stent thrombosis: insights from optical coherence tomography. J Thorac Dis 2016
  11. E460-2. [Crossref] 11. Kamenik M, Widimsky P. Stent thrombosis in acute coronary syndromes: Patient-related factors and operator-related factors. Anatol J Cardiol 2020
  12. [Crossref] 12. Sudhir K, Hermiller JB, Ferguson JM, Simonton CA. Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy. ISRN Cardiol 2013
  13. 748736. [Crossref] 13. Park DW, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009
  14. [Crossref] 14. Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, et al. White Blood Cell Count and Major Adverse Cardiovascular Events After Percu